LONDON, January 18, 2022 /PRNewswire/ — Dragonfly Biosciences Limited, the makers of Dragonfly CBD, Europe largest and leading range of CBD oils and skincare products from seed to shelf, are pursuing a strategy to become a global leader in fast wellness. Building on its market leadership across the UK, Dragonfly went public on the Australian Stock Exchange last month (December 2021). Public ownership was just one strategic element establishing an Australian beachhead at the center of an Indo-Pacific market offensive to capture key growth economies. To achieve robust market penetration throughout United States of America, Thought Leaders Inc., have been engaged under a Heads of Agreement broadly focused on achieving high-performance goals across all US market sectors.
thought leader, a US-based health, wellness and intellectual property research and development and investment company, announced today that it has secured an exclusive US master license for Dragonfly Biosciences, one of the world’s most respected CBD brands.
Thought Leaders plans to launch Dragonfly’s premium CBD-infused wellness products in the United States, the world’s largest market for CBD-infused wellness products, in mid-2022. Thought Leaders is planning a comprehensive, groundbreaking direct sales program alongside traditional retail sales in select channels. In parallel, Thought Leaders plans to develop unique products and launch new segments for the US based on solid R&D protocols under the Dragonfly brand, to be exported to established international markets.
Regan Saveall, Chairman of the Board Dragonfly Biosciences Ltd, says: “With an award-winning number one CBD brand in the UK, we are delighted to partner with Thought Leaders, Inc. in The United States under a master license agreement to manage US sales and support all our markets with their experience and expertise in the consumer goods industry. Thought leaders will work with our local US team to ensure our business practices are integrated. Thought Leaders will offer US consumers our proprietary formulations, backed by extensive research, and develop new, unique products, backed by our physicians, who will lead new categories in all of our markets. Our strict quality controls in all manufacturing processes to ensure the highest and most consistent product quality will be maintained, with all innovations to meet the latest consumer needs as we aspire to become a global leader in wellness and free ourselves from the Covid 19 pandemic to recover.”
Mark Singleton, President and CEO of Thought Leaders, added, “We are very pleased to add Dragonfly’s US master license agreement to our select portfolio of premium brands, products and technologies that reflect Thought Leaders’ vision. We believe Dragonfly’s brand strength, credibly built on its groundbreaking and clinically proven consumer products, will be well received by US consumers and retailers alike.”
Notes for editors:
Dragonfly Biosciences Ltd is a UK based company with an international reach. Dragonfly was named “Best CBD Product” by one of the world’s most respected health and beauty retailers and pharmacy chain in 2020 and was voted the #1 Recommended CBD Brand by Boots customers in 2021. The Dragonfly brand has an established distribution through leading retailers and direct to consumer channels to offer consumers proprietary products that are manufactured from seed to shelf.
Supported by experts in farming, cultivation, extraction, formulation, compliance and education, consumers can be assured of the highest quality and consistent standards that meet regulations. These values are implemented in all of their markets.
About Thought Leaders Inc.
Thought Leaders Inc is a specialty investment firm focused on the CBD and botanical health and wellness sectors. Founded by a team of professionals with a proven track record in the luxury and lifestyle industries who recognize the true potential of this market. Their investment and established network are able to lead the category and build equity as the regulatory landscape evolves based on standards, compliance and ethical practices. Thought Leaders develops and commercializes disruptive brands and intellectual property focused on health and wellness that deliver a superior consumer experience. They are leaders in the US CBD market and the adult and medical cannabis sectors in existing permitted states and are preparing for federal regulation. Thought Leaders is committed to advancing public health by adopting its technology under licensing agreements. Their leadership and advisory teams bring unparalleled experience and skills to capitalize on opportunities in fragmented, compliant categories. Through their research and development activities in the US and in international markets, Thought Leaders offer a unique combination of products, global sales potential and innovation capabilities. Thought Leaders is poised to revolutionize health and wellness product categories in this sector, working with exclusive brands that are authentic and innovative, with strong management teams. Thought Leaders’ unique combination of products, global distribution potential and innovation capabilities is poised to revolutionize health and wellness product categories and deliver outstanding shareholder returns.
SOURCE Dragonfly Biosciences